부산대학교 도서관

Purpose: Unique treatments of esophageal squamous cell carcinoma (ESCC) in our hospital are neoadjuvant chemotherapy using docetaxel/CDDP/5-FU in cStage II/III (excluding cT4) cases, and chemoradiotherapy using docetaxel/CDDP/5-FU in cT4 or cM1 lymph node metastasis cases. We herein report prognostic analysis of ESCC in a prospective database determined by treatment strategy based on a cancer board. Materials and Methods: Between January 2009 and March 2016, prognostic analyses were performed based on a prospective database of 504 ESCC debated on an esophageal cancer board. Result: (1) Five-year overall survival rate for each cStage (I/IIA/IIB/III/IV) in the surgical treatment cases were 88.3/85.2/83.8/55.8/66.7%, respectively. (2) In the cases of surgical treatment in cStage I/IIB, five-year disease specific survival rate was very good: 95.3/90.2%, respectively. In cStage IIB, neoadjuvant chemotherapy was administered to 90.5% of cases. (3) Surgical treatment outcomes in cStage IIA/III cases were significantly better than nonsurgical treatments except for cT4 cases with poor prognosis (P=0.0229). (4) Long-term survival cases in cStage IV was those with conversion surgery for positive para aortic lymph node metastasis cases. Conclusion: Prognosis was deemed to be optimized by multidisciplinary treatment decision based on esophageal cancer board. Especially, the prognosis of surgical treatment cases was the best and it was considered to be the most recommended treatment at present.